, China

Chinese vaccines remain vital in developing nations despite criticisms

Developing nations face inadequate supply as developed nations stockpiled vaccines from top manufacturers.

Amidst the global demand for COVID-19 vaccines and the supply-demand gaps, Chinese vaccines remain crucial for developing nations’ vaccination programs despite criticisms regarding real-world data on the vaccines’ efficacy, according to a report from GlobalData.

The country has so far provided COVID-19 vaccine aid to more than 50 developing nations. However, Chinese vaccines were criticized for lack of peer-reviewed data over their efficacy in Phase III trials.

GlobalData’s Pharma Analyst Prashant Khadayate commented that Chinese vaccines have shown varied efficacy rates across countries in clinical trial settings from over 50% to 79%, and real-world data appeared to validate the data observed in a clinical trial setting.

“However, low efficacy observed in real-world data will not hurt the future uptake as developed nations have already stockpiled large quantities of COVID-19 vaccines from leading manufactures... leading to inadequate supply for developing nations,” Khadayate said.

Amongst the top 15 economies, Brazil and Mexico are the only two countries that have approved Chinese vaccines. GlobalData noted that most of the COVID-19 vaccines being supplied to developing countries are by companies based out of Russia, China, and India.

However, India is currently struggling with a severe second wave of COVID-19 and the focus is shifting towards vaccinating its own population and less towards supplying other nations.

As a result, the WHO-backed COVAX initiative has slashed the number of vaccines to be delivered by end-May from about 240 million doses to 145 million. The initiative was also only able to supply 41 million doses so far of its two billion doses promised by the end-2021.

“Chinese vaccine manufacturers are already playing a key role in supplying vaccines to developing countries. The supply of COVID-19 vaccines from China are expected to improve further and be of increased importance amid the supply issues within India in the wake of second wave of COVID-19,” Khadayate said.

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Get Health Care Asia Magazine in your inbox
It was recognised for its cutting-edge medical device packaging design, Dispenser Integrated System Kit (DISK).
There has been an expanding research base across India, China, and Japan.
It combines third-party assured data verification with blockchain technology.
Consultation is available for only $0.014 (INR1).
The number of hospitals operating on hip fracture that have access to a fracture liaison service has been steadily rising from 2013 to 2020.
GMT Manila’s award-winning initiative, in collaboration with Endec Inc. and Scilore LLC, is a rapidly deployable turnkey solution for RT-PCR Testing that made it more available across the Philippines. 
As The National Cardiovascular Referral Center in Indonesia, NCCHK has been acknowledged by Asia's Healthcare Industry.
Currently, North America dominates the market across the globe.
More medical devices are being bought for home use.
It has also introduced a new hotline service.
The firm was recognised for its multiple initiatives in braving the COVID-19 crisis.
It took home the Training Initiative of the Year trophy for its non-invasive therapy treatment for benign prostatic hyperplasia (BPH).
The country’s SII makes up about half of Covax supply.
It owns 39 hospitals and eight clinics across England, Wales, and Scotland.
The company plans to set up over 100 in-school clinics.